Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been assigned an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $22.80.

Several brokerages have recently issued reports on ZVRA. Weiss Ratings restated a “sell (d+)” rating on shares of Zevra Therapeutics in a research note on Friday, January 9th. Cantor Fitzgerald reduced their price objective on Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. HC Wainwright set a $26.00 price target on Zevra Therapeutics in a research report on Tuesday, December 30th. Finally, Canaccord Genuity Group decreased their price objective on Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, November 6th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ZVRA. Marshall Wace LLP purchased a new stake in shares of Zevra Therapeutics during the third quarter worth $8,676,000. Rubric Capital Management LP raised its stake in shares of Zevra Therapeutics by 60.8% during the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock valued at $17,253,000 after purchasing an additional 740,584 shares during the period. Royce & Associates LP purchased a new stake in Zevra Therapeutics during the 3rd quarter worth about $6,574,000. Adage Capital Partners GP L.L.C. lifted its holdings in Zevra Therapeutics by 15.2% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after purchasing an additional 550,000 shares in the last quarter. Finally, Nantahala Capital Management LLC boosted its stake in Zevra Therapeutics by 34.0% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock worth $18,753,000 after purchasing an additional 500,000 shares during the period. 35.03% of the stock is owned by institutional investors.

Zevra Therapeutics Trading Up 1.6%

NASDAQ ZVRA opened at $9.00 on Friday. The business’s fifty day moving average is $8.64 and its 200-day moving average is $9.50. The company has a debt-to-equity ratio of 0.46, a current ratio of 8.62 and a quick ratio of 8.57. The stock has a market capitalization of $506.68 million, a price-to-earnings ratio of 19.15 and a beta of 1.08. Zevra Therapeutics has a one year low of $6.19 and a one year high of $13.16.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. The business had revenue of $26.06 million during the quarter, compared to the consensus estimate of $26.64 million. Zevra Therapeutics had a net margin of 41.93% and a negative return on equity of 51.40%. Equities research analysts predict that Zevra Therapeutics will post -1.95 EPS for the current year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.